LVRS (n=34) | BLVR (n=46) | |||||||
Subjects | Events | Subjects | Events | |||||
<30 days | 1–12 months | <30 days | 1–12 months | <30 days | 1–12 months | <30 days | 1–12 months | |
Any haemoptysis | 1 (2.9) | 0 | 1 | 0 | 2 (4.3) | 2 (4.3) | 2 | 2 |
Massive haemoptysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Mortality | 0 | 1 (2.9) | 0 | 1 | 1 (2.2) | 0 | 1 | 0 |
AE-COPD requiring hospitalisation | 2 (5.9) | 1 (2.9) | 2 | 1 | 2 (4.3) | 7 (15.2) | 2 | 7 |
AE-COPD requiring NIV | 0 | 0 | 0 | 0 | 1 (2.2) | 0 | 1 | 0 |
AE-COPD requiring ICU stay | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AE-COPD treated at home | 8 (23.5) | 3 (8.8) | 10 | 3 | 9 (19.6) | 6 (13.0) | 19 | 6 |
Pneumonia | 0 | 1 (2.9) | 0 | 1 | 2 (4.3) | 1 (2.2) | 2 | 2 |
Pneumothorax | 14 (30.4) | 1 (2.2) | 14 | 1 | ||||
Post-surgical air leak | 4 (11) | 0 | 5 | 0 | ||||
Respiratory failure | 1 (2.9) | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Subcutaneous emphysema | 12 (35.3) | 0 | 12 | 0 | 1 (2.2) | 0 | 1 | 0 |
Valve migration | 2 (4.3) | 0 | 2 | 0 | ||||
Valve removal | 2 (4.3) | 1 (2.2) | 3 | 1 | ||||
Other repeat procedure | 2 (4.3) | 0 | 2 | 0 | 5 (10.9) | 0 | 5 | 0 |
Prolonged stay post-procedure | 11 (32.4) | 13 (28.3) |
Data are presented as n (%) or n. LVRS: lung volume reduction surgery; BLVR: bronchoscopic lung volume reduction; AE: acute exacerbation; NIV: non-invasive ventilation; ICU: intensive care unit. Serious adverse events were events leading to death, hospitalisation or prolongation of existing hospitalisation, persistent or significant disability/incapacity, or to serious deterioration in health that resulted in a life-threatening illness or injury, a permanent impairment of a body structure or body function. Prolonged length of stay defined as >10 days in LVRS and >4 days in BLVR.